Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

Catherine L. Forse, Seema Agarwal, Dushanthi Pinnaduwage, Frank Gertler, John S. Condeelis, Juan Lin, Xiaonan Xue, Kimberly Johung, Anna Marie Mulligan, Thomas E. Rohan, Shelley B. Bull, Irene L. Andrulis

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Background: Menacalc is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Menacalc and risk of death from breast cancer. Our goal was to determine if Menacalc could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer. Methods: Analysis of the association of Menacalc with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Menacalc with risk of death after adjustment for HER2 status and clinicopathological tumor features. Results: High Menacalc was associated with increased risk of death from any cause (P = 0.0199, HR (CI) = 2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Menacalc cohort which did not receive hormone or chemotherapy (n = 142) (P = 0.0052, HR (CI) = 3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Menacalc in the HER2, basal and luminal molecular subtypes. Conclusions: Menacalc may serve as an independent prognostic biomarker for the ANN breast cancer patient population.

Original languageEnglish (US)
Article number483
JournalBMC Cancer
Issue number1
StatePublished - Jun 27 2015


  • Axillary node negative
  • Breast cancer
  • Mena
  • Metastasis
  • Prognostic marker

ASJC Scopus subject areas

  • Genetics
  • Oncology
  • Cancer Research


Dive into the research topics of 'Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer'. Together they form a unique fingerprint.

Cite this